Cargando…

Income and antiplatelet adherence following percutaneous coronary intervention

OBJECTIVE: To investigate the relation of annual household income to antiplatelet adherence following PCI. BACKGROUND: Treatment with 6–12 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) is a Class I recommendation. Adherence to these medications is esse...

Descripción completa

Detalles Bibliográficos
Autores principales:	LaRosa, Anna R., Swabe, Gretchen M., Magnani, Jared W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434414/ https://www.ncbi.nlm.nih.gov/pubmed/36060289 http://dx.doi.org/10.1016/j.ijcrp.2022.200140

Ejemplares similares

Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention
por: Lapa, Matthew E., et al.
Publicado: (2022)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
por: Schikowski, Erin M., et al.
Publicado: (2022)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Association between income and likelihood of right heart catheterization in individuals with pulmonary hypertension: A US claims database analysis
por: Schikowski, Erin M., et al.
Publicado: (2022)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Racial and Ethnic Differences in Cardiac Rehabilitation Participation: Effect Modification by Household Income
por: Garfein, Joshua, et al.
Publicado: (2022)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Hyphema: A Rare Complication of Periprocedural Antiplatelets and Anticoagulants Following Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Association of Race and Ethnicity on the Management of Acute Non−ST‐Segment Elevation Myocardial Infarction
por: Tertulien, Tarryn, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
por: Wang, Yehua, et al.
Publicado: (2023)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
por: Essien, Utibe R., et al.
Publicado: (2023)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
por: Mourikis, Philipp, et al.
Publicado: (2023)

Percutaneous Coronary Intervention in the Elderly
por: Walsh, Simon J, et al.
Publicado: (2007)

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
por: Kandzari, David E., et al.
Publicado: (2020)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
por: Remillard, Taylor C., et al.
Publicado: (2021)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

Association of household income and adverse outcomes in patients with atrial fibrillation
por: LaRosa, Anna Rose, et al.
Publicado: (2020)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
por: Ostojic, Zvonimir, et al.
Publicado: (2021)

Spontaneous subdural hematoma in a patient receiving dual antiplatelet therapy following percutaneous coronary intervention: A case report
por: Bouhaddoune, Youssra, et al.
Publicado: (2021)

Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
por: Mshelbwala, Fakilahyel S, et al.
Publicado: (2020)

Association of Frailty With Antiplatelet Response Among Elderly Chinese Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yang, et al.
Publicado: (2020)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

One-year follow-up of patients treated with single antiplatelet therapy directly after percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome
por: van der Sangen, Niels M R, et al.
Publicado: (2023)

The effect of early dual antiplatelet timing on the microvascular resistance and ventricular function in primary percutaneous coronary intervention
por: Firman, Doni, et al.
Publicado: (2020)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Percutaneous Coronary Intervention With Dual Antiplatelet Therapy in a Patient With Chronic Subdural Hematoma: Novel Approach
por: Etuk, Aniekeme S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4nkc512vq2276lh7nq77f3ks9o